Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $110
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Geulah Livshits maintains a 'Buy' rating on CRISPR Therapeutics (NASDAQ:CRSP), but has lowered the price target from $123 to $110.
August 08, 2023 | 8:32 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Chardan Capital maintains a 'Buy' rating on CRISPR Therapeutics but lowers the price target from $123 to $110.
The news is directly related to CRISPR Therapeutics as the analyst from Chardan Capital has maintained a 'Buy' rating but lowered the price target. This could indicate a potential decrease in the short-term performance of the stock, but the 'Buy' rating suggests a positive long-term outlook. Therefore, the short-term impact score is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100